AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03757026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harnessed gaming
Description: 20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
Study NCT04993144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous theta burst stimulation
Description: stimulatory protocol
Study NCT04993144 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation
Description: stimulatory protocol
Study NCT01041872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-lipuro B. Braun plain
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study NCT03484546 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma cyst excision
Description: laparoscopic resection of ovarian endometrioma
Study NCT01041872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-lipuro B. Braun plus lidocaine
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study NCT01041872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Fresenius plain
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Study NCT01041872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Fresenius plus lidocaine
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study NCT03930706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longer administration of estradiol (Progynova®)
Description: All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
Study NCT03930706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longer administration of estradiol (Progynova®)
Description: All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
Study NCT03673020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Description: Neoantigen Vaccine
Study NCT04356963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Session (VR Blu)
Description: 20-30 minute session of virtual reality immersive content.
Study NCT04356963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based Session (Tablet Blu)
Description: 20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
Study NCT04356963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality Head Mounted Display without Content (VR Blank)
Description: 20-30 minutes session using head mounted display to reduce light and sound.
Study NCT02894177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tcPCO2 measurement
Description: tcPCO2 continuous monitoring during spontaneous breathing trials
Study NCT01602250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min
Study NCT01602250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid®
Description: Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
Study NCT03779711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous (self) mononuclear cells derived from umbilical cord blood
Description: The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
Study NCT03779711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stage II Surgical repair
Description: This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
Study NCT03779711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stage II Surgical repair
Description: This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
Study NCT00649896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Estradiol Transdermal System 0.025 mg/day
Study NCT00676832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solid capsule dosage form administered orally once daily.
Study NCT00676832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED
Description: The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
Study NCT00649896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Climara® Transdermal System 0.025 mg/day
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 1
Description: SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 2
Description: SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB213503 lot 3
Description: SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix
Description: Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPOL
Description: IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
Study NCT00148941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
Study NCT03050320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
Study NCT03050320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Exercise
Description: A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
Study NCT02668913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic analysis
Description: Molecular profiling
Study NCT02971553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Resuscitator with PEEP
Study NCT02971553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upright Resuscitator
Study NCT00995657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Inhaled Fluticasone Propionate 50mcg bid
Study NCT00995657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Inhaled Fluticasone Propionate 250mcg bid
Study NCT01596036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early appointment (within 10 days)
Description: Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
Study NCT01596036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine referral (at 5 weeks)
Description: Standard Referral to Cardiac Rehabilitation
Study NCT01651663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol (Umifenovir)
Description: Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
Study NCT01651663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
Study NCT01651663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol (Umifenovir)
Description: Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
Study NCT01651663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
Study NCT03997656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyDiPP (Malaysia Diabetes Prevention Program)
Description: The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
Study NCT01757288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB-PACLITAXEL
Description: nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
Study NCT00085449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT00085449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00085449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00085449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00085449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00085449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00085449 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04286516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Paired pulse transcranial magnetic stimulation
Study NCT04720092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Granules for oral suspension, 10 mg, oral, single dose
Study NCT04720092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablet, 10 mg, oral, single dose
Study NCT02828020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: 50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02828020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02828020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02727491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
Study NCT02727491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
Study NCT02769169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis® (Raibizumab) double-dose
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
Study NCT02769169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis® (Raibizumab) regular-dose
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
Study NCT01183065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate With Vitamin B12 and Folic Acid
Description: Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
Study NCT01870648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study NCT01870648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study NCT02394717 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Eating and Physical Activity
Description: Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
Study NCT00330681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study NCT00330681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-186
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study NCT05374629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use different methods of teaching
Description: Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
Study NCT00621140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: active
Study NCT00621140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01656668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC1036
Study NCT03870412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
Study NCT00360568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Study NCT00360568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00360568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00360568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study NCT02689167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study NCT02689167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT00627055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
Study NCT00627055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r + TDF/FTC or TDF/3TC
Description: TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
Study NCT03728179 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib
Description: Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated
Study NCT00973245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 10mg od
Study NCT00973245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 15mg od